FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2956018262> ?p ?o ?g. }

• W2956018262 endingPage "1043" @default.
• W2956018262 startingPage "1043" @default.
• W2956018262 abstract "Thrombotic microangiopathy is a complex disorder associated with thrombocytopenia, microangiopathic hemolytic anemia (MAHA) and organ damage. The disorder can be seen in association with deficiencies of ADAMTS 13, Thrombotic Thrombotic Purpura (TTP) or due to dysregulation of the complement system, atypical Hemolytic Syndrome (aHUS). Lupus erythematosus is a multisystem immune complex disorder often associated with renal insufficiency due to glomerulonephritis, lupus nephritis (LN). TMA with progressive, life threatening thrombocytopenia, MAHA and worsening renal function can occur in these patients, despite of high dose glucocorticoids, plasmapheresis and other immune modulatory therapy. Because the clinical and laboratory presentation is indistinguishable from aHUS, the use of complement inhibition is appropriate. We present 8 cases of LN, refractory to plasma exchange (PEX), glucocorticoids, and immune therapies, who were treated with eculizumab, a monoclonal antibody to complement C5. Patients and Methods: We retrospectively reviewed the cases of 8 patient with SLE and aHUS diagnosed from 2009 to 2016 hospitalized at 2 large urban hospitals. The age mean, median, and range was 34.5, 34, and 21 to 59 years, respectively. The majority of patients were women (7/8). There was evidence of renal insufficiency, hemolytic anemia (elevated LDH, low haptoglobin, fragmented red blood cells), and thrombocytopenia on admission. The mean Cr was 3.1 mg/dL (median Cr 2.5, range 1.5-5.7), mean Hgb was 8.2 g/dL (median 8.4, range 5.4-11.7), mean platelets was 65.4 (median 78, range 8-91). 5/8 patients had renal biopsies which demonstrated TMA. in all cases, ADAMTS13 activity was greater the 5%. Results: 7/8 patients responded to the eculizumab, with reduction in lactic dehydrogenase (LDH), improvement in thrombocytopenia to greater than 100 x 109/L, improvement in renal function, and anemia. 5/8 (63%) of patients were on hemodialysis during hospitalization; of the five patients on dialysis, 1 patient expired, 2 continued dialysis, and 2 were able to discontinue dialysis on follow-up. Of the 5 dialysis patients, 1 stopped dialysis on day 1 of treatment and another patient stopped on day 60 post-eculizumab. Of the 2 patients who continued dialysis, 1 patient had a previous history of an allogeneic renal transplant which was compromised by graft loss due to aHUS; renal biopsy showed evidence of thrombotic microangiopathy and graft rejection. She was positive for a thrombomodulin mutation. 7/7 living patients were screened for genetic complement mutations. Mutations were detected in 4/7 (57%) ,including complement factor H, thrombomodulin, factor B, CFHR5 and membrane co-factor protein (MCP/CD46). All patients were treated with eculizumab per the FDA approved schedule, given meningococcal vaccinations and penicillin prophylaxis. 1 patient died with progressive TMA within 1 day of receiving eculizumab. Autopsy showed TMA and disseminated fungal infection. There were no infectious complications associated with eculizumab. 6/7 surviving patients have continued on eculizumab. 1 patient elected to discontinue treatment after 1 year. She did not have any identified mutations. CONCLUSIONS: Complement inhibition, with eculizumab, is an effective treatment of patients with progressive lupus nephritis associated TMA and represents a new paradigm in treatment for this devastating disorder. Disclosures Weitz: Alexion Pharmaceuticals: Speakers Bureau." @default.
• W2956018262 created "2019-07-12" @default.
• W2956018262 creator A5048809724 @default.
• W2956018262 creator A5056971594 @default.
• W2956018262 date "2017-12-07" @default.
• W2956018262 modified "2023-09-29" @default.
• W2956018262 title "Effective Treatment of Thrombotic Microangiopathy Associated with Lupus Nephritis with Eculizumab: a Series of 8 Cases" @default.
• W2956018262 doi "https://doi.org/10.1182/blood.v130.suppl_1.1043.1043" @default.
• W2956018262 hasPublicationYear "2017" @default.
• W2956018262 type Work @default.
• W2956018262 sameAs 2956018262 @default.
• W2956018262 citedByCount "0" @default.
• W2956018262 crossrefType "journal-article" @default.
• W2956018262 hasAuthorship W2956018262A5048809724 @default.
• W2956018262 hasAuthorship W2956018262A5056971594 @default.
• W2956018262 hasConcept C111684460 @default.
• W2956018262 hasConcept C126322002 @default.
• W2956018262 hasConcept C159654299 @default.
• W2956018262 hasConcept C203014093 @default.
• W2956018262 hasConcept C2776874634 @default.
• W2956018262 hasConcept C2776912625 @default.
• W2956018262 hasConcept C2777637130 @default.
• W2956018262 hasConcept C2777878052 @default.
• W2956018262 hasConcept C2777991916 @default.
• W2956018262 hasConcept C2778585876 @default.
• W2956018262 hasConcept C2778842783 @default.
• W2956018262 hasConcept C2779134260 @default.
• W2956018262 hasConcept C2779912601 @default.
• W2956018262 hasConcept C2780868729 @default.
• W2956018262 hasConcept C2781127562 @default.
• W2956018262 hasConcept C71924100 @default.
• W2956018262 hasConcept C89560881 @default.
• W2956018262 hasConcept C90924648 @default.
• W2956018262 hasConceptScore W2956018262C111684460 @default.
• W2956018262 hasConceptScore W2956018262C126322002 @default.
• W2956018262 hasConceptScore W2956018262C159654299 @default.
• W2956018262 hasConceptScore W2956018262C203014093 @default.
• W2956018262 hasConceptScore W2956018262C2776874634 @default.
• W2956018262 hasConceptScore W2956018262C2776912625 @default.
• W2956018262 hasConceptScore W2956018262C2777637130 @default.
• W2956018262 hasConceptScore W2956018262C2777878052 @default.
• W2956018262 hasConceptScore W2956018262C2777991916 @default.
• W2956018262 hasConceptScore W2956018262C2778585876 @default.
• W2956018262 hasConceptScore W2956018262C2778842783 @default.
• W2956018262 hasConceptScore W2956018262C2779134260 @default.
• W2956018262 hasConceptScore W2956018262C2779912601 @default.
• W2956018262 hasConceptScore W2956018262C2780868729 @default.
• W2956018262 hasConceptScore W2956018262C2781127562 @default.
• W2956018262 hasConceptScore W2956018262C71924100 @default.
• W2956018262 hasConceptScore W2956018262C89560881 @default.
• W2956018262 hasConceptScore W2956018262C90924648 @default.
• W2956018262 hasLocation W29560182621 @default.
• W2956018262 hasOpenAccess W2956018262 @default.
• W2956018262 hasPrimaryLocation W29560182621 @default.
• W2956018262 hasRelatedWork W1537023805 @default.
• W2956018262 hasRelatedWork W1986613143 @default.
• W2956018262 hasRelatedWork W1986736016 @default.
• W2956018262 hasRelatedWork W2006084243 @default.
• W2956018262 hasRelatedWork W2011886180 @default.
• W2956018262 hasRelatedWork W2069570581 @default.
• W2956018262 hasRelatedWork W2134940901 @default.
• W2956018262 hasRelatedWork W2161969227 @default.
• W2956018262 hasRelatedWork W2305176160 @default.
• W2956018262 hasRelatedWork W2554111157 @default.
• W2956018262 hasRelatedWork W2557854875 @default.
• W2956018262 hasRelatedWork W2594953432 @default.
• W2956018262 hasRelatedWork W2782984432 @default.
• W2956018262 hasRelatedWork W2790825384 @default.
• W2956018262 hasRelatedWork W2890636034 @default.
• W2956018262 hasRelatedWork W2924983547 @default.
• W2956018262 hasRelatedWork W2963206907 @default.
• W2956018262 hasRelatedWork W2979836772 @default.
• W2956018262 hasRelatedWork W3036509333 @default.
• W2956018262 hasRelatedWork W3213074348 @default.
• W2956018262 hasVolume "130" @default.
• W2956018262 isParatext "false" @default.
• W2956018262 isRetracted "false" @default.
• W2956018262 magId "2956018262" @default.
• W2956018262 workType "article" @default.